Morin is a bioactive polyphenol derived from plants. However, its inadequate biopharmaceutical properties impede its therapeutic effectiveness. Hence this study focused on developing a nanoparticle (NP) formulation of morin to improve its oral bioavailability and bioactivity. Materials and methods: MoR was encapsulated in lipid-cored poly(lactide-co-glycolide) (PLGA) nanoparticles by using the emulsification-solvent evaporation process. The formulated NP was subjected to physiochemical characterization, TEM analysis, in-vitro drug release, and in-vivo behavioral study. Results: The formulated nanoparticles (NPs) had a loading efficiency of 80%, a size of around 211 nm, and an essentially neutral surface charge. In 24 hours of duration, the NPs showed a continuous release of MoR. When oral administration of either free or MoR-PLGA NPs was used, a pharmacokinetic analysis of the plasma and brain accumulation revealed that, while the initial MoRconcentrations were identical in both situations, the long-term (5-24 hours) concentrations were about 5 times greater with MoR-PLGA NPs. In-vivo analysis showed that MoR-PLGA NPssignificantly enhanced memory and spatial learning. Conclusion: The study's findings provide a potentially effective NP formulation for MoR that may improve its oral bioavailability and bioactivity in the context of treating Alzheimer's disease